Modi’in, Israel, Dec. 31, 2015 – Silenseed, a leading RNAi-based therapeutics company, today announced the construction of a class-A GMP clean room facility in the new company office Modi’in. The new facility will enable in-house production of the company’s lead product, siG12D-LODER, to support the Phase 2 study in Locally Advanced Pancreatic Cancer (NCT01676259)